Teva launches generic EpiPen Jr. in the United States – Teva Pharmaceutical Industries Limited (NYSE: TEVA)



[ad_1]

Teva Pharmaceutical Industries (NYSE: TEVA) Announces US Commercial Launch of its Generic Version of Mylan's Emergency Auto-Injector (NASDAQ: MYL) with EpiPen Jr (Epinephrine Injection) , USP), 0.15 mg.

The wholesale purchase cost (WAC) is 300 USD for a pack of 2.

The generic equivalent of Teva, EpiPen and EpiPen Jr, uses Antares Pharma's push button VIBEX auto-injector (NASDAQ: ATRS).

In the United States, EpiPen has been in short supply for more than a year. The demand for Teva's offer should therefore be strong.

TEVA is in place 1% before marketing while MYL is down by a fraction.

[ad_2]

Source link